WNK2 and cancer: Up-regulations of melatonin receptors in cancer cells lead to inhibition of some protein kinases (PKA, protein kinase A; PKC, protein kinase C; MAPK, mitogen-activated protein kinase), decrease the phosphorylation of transcription factors, i.e., CREB (cAMP response element-binding) and reduce the expression of genes associated with the process of proliferation [25,45].